

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

**COMPLETION OF THE DISCLOSEABLE
TRANSACTION IN RELATION TO
THE DEEMED DISPOSAL OF EQUITY INTEREST IN
LEGEND BIOTECH IN RELATION TO
THE PRIVATE PLACEMENT**

Reference is made to the announcement of the Company dated 20 April 2023 relating to the Private Placement of Legend Biotech Corporation (the “**Previous Announcement**”). Unless otherwise defined, terms used in this announcement shall have the same meanings given to them in the Previous Announcement.

The Board is pleased to announce that all of the conditions of the Subscription Agreement have been fulfilled and the Closing of the Private Placement took place on 24 April 2023 (New York time). Upon the Closing, the Investor holds 7,656,968 Legend Biotech Shares from this Private Placement.

The shareholding structure of Legend Biotech immediately after the Closing is, to the best knowledge of the Company, set out below:

Name of the Shareholders	Legend Biotech Shares	ADSs⁽¹⁾	Shareholding percentage immediately after the Closing	Shareholding Percentage immediately after the Closing on the Fully Diluted Basis⁽²⁾
Company	174,497,556	87,248,778	51.54%	48.51%
The Investor	12,529,414	6,264,707	3.70%	3.48%
Other Shareholders	151,559,130	75,779,565	44.76%	42.13%
Legend ESOP ⁽³⁾	21,162,128	10,581,064	-	5.88%
Total	359,748,228	179,874,114	100.00%	100.00%

Notes:

- (1) Each ADS will represent two Legend Biotech Shares.
- (2) The shareholding percentages are calculated on the Fully Diluted Basis assuming (i) all the Legend ESOP Shares are allotted and issued, and (ii) the Legend Warrant has been fully exercised.
- (3) The employee stock ownership plan of Legend (the “**Legend ESOP**”) includes (i) the share option scheme of Legend Biotech adopted and approved by the shareholder of the Legend Biotech on 21 December 2017, pursuant to which a maximum of 20,000,000 Legend Biotech Shares may be issued upon the exercise of the options granted thereunder, and (ii) a share incentive plan of Legend Biotech

adopted and approved by the shareholder of Legend Biotech on 26 May 2021, pursuant to which a maximum of 11,000,000 Legend Biotech Shares may be issued pursuant to the vesting of the restricted stock units granted thereunder. The exercise of the options granted or to be granted, and the vesting of the restricted stock units to be granted under the Legend ESOP shall be subject to a vesting schedule as specified in the relevant scheme documents.

Shareholders and potential investors of the Company should therefore exercise caution when dealing in or investing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 25 April 2023

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai

** For identification purposes only*